. ?& `3 N k0 ~
临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究: 2 f. ]8 \+ y; l: L1 |Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.: V" ]8 o. I( d http://www.ncbi.nlm.nih.gov/pubmed/229681847 e; U U3 n+ @9 U( T/ X I
* Y# r s5 O0 H# ^4 x+ H
依维莫司联合吉非替尼抑制非小细胞肺癌细胞系的效果和作用机制 - H- s- p$ o! V: Ihttp://d.wanfangdata.com.cn/Thesis_Y1770447.aspx